Asset
AB-836
Arbutus Biopharma Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04775797 | phase1 | terminated | 2021-06-25 | 2022-11-17 | Arbutus Biopharma Corporation | Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection |
FDA applications (0)
This company has no applications containing this asset.